

# Miguel Bernardo

## List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/1796120/publications.pdf>

Version: 2024-02-01

399  
papers

12,115  
citations

34076

52  
h-index

53190

85  
g-index

450  
all docs

450  
docs citations

450  
times ranked

10718  
citing authors

#	ARTICLE	IF	CITATIONS
1	The contribution of cannabis use to variation in the incidence of psychotic disorder across Europe (EU-GEI): a multicentre case-control study. <i>Lancet Psychiatry</i> , 2019, 6, 427-436.	3.7	528
2	Double-Blind, Placebo-Controlled Comparison of Intramuscular Olanzapine and Intramuscular Haloperidol in the Treatment of Acute Agitation in Schizophrenia. <i>American Journal of Psychiatry</i> , 2001, 158, 1149-1151.	4.0	258
3	Standardized remission criteria in schizophrenia. <i>Acta Psychiatrica Scandinavica</i> , 2006, 113, 91-95.	2.2	238
4	Treated Incidence of Psychotic Disorders in the Multinational EU-GEI Study. <i>JAMA Psychiatry</i> , 2018, 75, 36.	6.0	235
5	Identifying Gene-Environment Interactions in Schizophrenia: Contemporary Challenges for Integrated, Large-scale Investigations. <i>Schizophrenia Bulletin</i> , 2014, 40, 729-736.	2.3	229
6	Metabolic profile of antipsychotic-naïve individuals with non-affective psychosis. <i>British Journal of Psychiatry</i> , 2009, 194, 434-438.	1.7	224
7	Assessment and management of agitation in psychiatry: Expert consensus. <i>World Journal of Biological Psychiatry</i> , 2016, 17, 86-128.	1.3	204
8	International trends in clozapine use: a study in 17 countries. <i>Acta Psychiatrica Scandinavica</i> , 2017, 136, 37-51.	2.2	188
9	International trends in antipsychotic use: A study in 16 countries, 2005–2014. <i>European Neuropsychopharmacology</i> , 2017, 27, 1064-1076.	0.3	185
10	Brain Effects of Cognitive Remediation Therapy in Schizophrenia: A Structural and Functional Neuroimaging Study. <i>Biological Psychiatry</i> , 2013, 73, 1015-1023.	0.7	162
11	Sustained attention impairment correlates to gray matter decreases in first episode neuroleptic-naïve schizophrenic patients. <i>NeuroImage</i> , 2003, 19, 365-375.	2.1	160
12	Pro-/Anti-inflammatory Dysregulation in Patients With First Episode of Psychosis: Toward an Integrative Inflammatory Hypothesis of Schizophrenia. <i>Schizophrenia Bulletin</i> , 2014, 40, 376-387.	2.3	156
13	Inflammation in schizophrenia: A question of balance. <i>Neuroscience and Biobehavioral Reviews</i> , 2015, 55, 612-626.	2.9	155
14	Amisulpride and olanzapine followed by open-label treatment with clozapine in first-episode schizophrenia and schizophreniform disorder (OPTiMiSE): a three-phase switching study. <i>Lancet Psychiatry</i> , 2018, 5, 797-807.	3.7	141
15	Examining the independent and joint effects of molecular genetic liability and environmental exposures in schizophrenia: results from the EUGEI study. <i>World Psychiatry</i> , 2019, 18, 173-182.	4.8	127
16	Prefrontal and temporal blood flow in schizophrenia: resting and activation technetium-99m-HMPAO SPECT patterns in young neuroleptic-naïve patients with acute disease. <i>Journal of Nuclear Medicine</i> , 1994, 35, 935-41.	2.8	119
17	Decreased cerebral activation during CPT performance. <i>NeuroImage</i> , 2004, 21, 840-847.	2.1	110
18	Criterios de valoración clínicos y de funcionamiento en un estudio de interacción gen-ambiente en primeros episodios psicóticos (PEPs). <i>Revista De Psiquiatría Y Salud Mental</i> , 2013, 6, 4-16.	1.0	99

#	ARTICLE	IF	CITATIONS
19	Cross-cultural Validation of the 5-Factor Structure of Negative Symptoms in Schizophrenia. <i>Schizophrenia Bulletin</i> , 2019, 45, 305-314.	2.3	99
20	Resilience and mental health during the COVID-19 pandemic. <i>Journal of Affective Disorders</i> , 2021, 283, 156-164.	2.0	98
21	Progressive gray matter changes in first episode schizophrenia: A 4-year longitudinal magnetic resonance study using VBM. <i>Schizophrenia Research</i> , 2009, 114, 136-143.	1.1	94
22	Telomere Length and Pulse Pressure in Newly Diagnosed, Antipsychotic-Naive Patients With Nonaffective Psychosis. <i>Schizophrenia Bulletin</i> , 2009, 35, 437-442.	2.3	92
23	Premorbid adjustment and clinical correlates of cognitive impairment in first-episode psychosis. The PEPsCog Study. <i>Schizophrenia Research</i> , 2015, 164, 65-73.	1.1	92
24	Prefrontal dysfunction in young acute neuroleptic-naive schizophrenic patients: A resting and activation SPECT study. <i>Psychiatry Research - Neuroimaging</i> , 1994, 55, 131-139.	0.9	89
25	The impact of cognitive reserve in the outcome of first-episode psychoses: 2-year follow-up study. <i>European Neuropsychopharmacology</i> , 2016, 26, 1638-1648.	0.3	89
26	Glucose abnormalities in the siblings of people with schizophrenia. <i>Schizophrenia Research</i> , 2008, 103, 110-113.	1.1	84
27	Paracingulate sulcus morphology in men with early-onset schizophrenia. <i>British Journal of Psychiatry</i> , 2003, 182, 228-232.	1.7	83
28	Regional cerebral blood flow pattern in normal young and aged volunteers: a99mTc-HMPAO SPET study. <i>European Journal of Nuclear Medicine and Molecular Imaging</i> , 1996, 23, 1329-1337.	2.2	81
29	Repetitive transcranial magnetic stimulation in the treatment of chronic negative schizophrenia: a pilot study. <i>Journal of Neurology, Neurosurgery and Psychiatry</i> , 1999, 67, 129-130.	0.9	80
30	Spanish version of the Screen for Cognitive Impairment in Psychiatry (SCIP-S): Psychometric properties of a brief scale for cognitive evaluation in schizophrenia. <i>Schizophrenia Research</i> , 2008, 99, 139-148.	1.1	78
31	Volume Changes in Gray Matter in First-Episode Neuroleptic-Naive Schizophrenic Patients Treated With Risperidone. <i>Journal of Clinical Psychopharmacology</i> , 2005, 25, 111-117.	0.7	76
32	Parental history of Type 2 diabetes in patients with nonaffective psychosis. <i>Schizophrenia Research</i> , 2008, 98, 302-306.	1.1	74
33	Prolactin concentrations in newly diagnosed, antipsychotic-naïve patients with nonaffective psychosis. <i>Schizophrenia Research</i> , 2012, 134, 16-19.	1.1	74
34	Peripheral Endocannabinoid System Dysregulation in First-Episode Psychosis. <i>Neuropsychopharmacology</i> , 2013, 38, 2568-2577.	2.8	73
35	Inflammatory markers in antipsychotic-naïve patients with nonaffective psychosis and deficit vs. nondeficit features. <i>Psychiatry Research</i> , 2012, 198, 212-215.	1.7	72
36	Abnormal glucose tolerance, white blood cell count, and telomere length in newly diagnosed, antidepressant-naïve patients with depression. <i>Brain, Behavior, and Immunity</i> , 2013, 28, 49-53.	2.0	71

#	ARTICLE	IF	CITATIONS
37	Neuroleptic Treatment Effect on Mitochondrial Electron Transport Chain. <i>Journal of Clinical Psychopharmacology</i> , 2007, 27, 284-288.	0.7	70
38	Effects of the COVID-19 pandemic and lockdown in Spain: comparison between community controls and patients with a psychiatric disorder. Preliminary results from the BRIS-MHC STUDY.. <i>Journal of Affective Disorders</i> , 2021, 281, 13-23.	2.0	70
39	Is Abnormal Glucose Tolerance in Antipsychotic-Naive Patients With Nonaffective Psychosis Confounded by Poor Health Habits?. <i>Schizophrenia Bulletin</i> , 2012, 38, 280-284.	2.3	69
40	Transdiagnostic dimensions of psychopathology at first episode psychosis: findings from the multinational EU-GEI study. <i>Psychological Medicine</i> , 2019, 49, 1378-1391.	2.7	69
41	Diez años de investigación traslacional colaborativa en enfermedades mentales: el CIBERSAM. <i>Revista De Psiquiatría Y Salud Mental</i> , 2019, 12, 1-8.	1.0	68
42	Cognitive reserve as an outcome predictor: first episode affective versus nonaffective psychosis. <i>Acta Psychiatrica Scandinavica</i> , 2018, 138, 441-455.	2.2	66
43	Evidence of activation of the Toll-like receptor-4 proinflammatory pathway in patients with schizophrenia. <i>Journal of Psychiatry and Neuroscience</i> , 2016, 41, E46-E55.	1.4	65
44	Cognitive mechanisms, psychosocial functioning, and neurocognitive rehabilitation in schizophrenia. <i>Schizophrenia Research</i> , 2003, 63, 219-227.	1.1	62
45	Spanish Validation Of the Brief Assessment in Cognition in Schizophrenia (Bacs) in Patients With Schizophrenia and Healthy Controls. <i>European Psychiatry</i> , 2011, 26, 69-73.	0.1	62
46	Subtypes of Memory Dysfunction Associated with ECT: Characteristics and Neurobiological Bases. <i>Journal of ECT</i> , 2001, 17, 129-135.	0.3	61
47	Differences in glucose tolerance between deficit and nondeficit schizophrenia. <i>Schizophrenia Research</i> , 2009, 107, 122-127.	1.1	60
48	Age at First Episode Modulates Diagnosis-Related Structural Brain Abnormalities in Psychosis. <i>Schizophrenia Bulletin</i> , 2016, 42, 344-357.	2.3	58
49	Social disadvantage, linguistic distance, ethnic minority status and first-episode psychosis: results from the EU-GEI case-control study. <i>Psychological Medicine</i> , 2021, 51, 1536-1548.	2.7	58
50	Lower striatal dopamine transporter binding in neuroleptic-naive schizophrenic patients is not related to antipsychotic treatment but it suggests an illness trait. <i>Psychopharmacology</i> , 2007, 191, 805-811.	1.5	57
51	Cognitive Remediation Therapy in Adolescents With Early-Onset Schizophrenia: A Randomized Controlled Trial. <i>Journal of the American Academy of Child and Adolescent Psychiatry</i> , 2014, 53, 859-868.	0.3	57
52	Abnormal glycemic homeostasis at the onset of serious mental illnesses: A common pathway. <i>Psychoneuroendocrinology</i> , 2016, 67, 70-75.	1.3	57
53	Utility of the World Health Organization Disability Assessment Schedule II in schizophrenia. <i>Schizophrenia Research</i> , 2012, 138, 240-247.	1.1	56
54	Electroconvulsive therapy in the treatment of mixed states in bipolar disorder. <i>European Psychiatry</i> , 2008, 23, 53-56.	0.1	55

#	ARTICLE	IF	CITATIONS
55	Neurocognitive diagnosis and cut-off scores of the Screen for Cognitive Impairment in Psychiatry (SCIP-S). <i>Schizophrenia Research</i> , 2010, 116, 243-251.	1.1	55
56	Spanish adaptation and validation of the Brief Negative Symptoms Scale. <i>Comprehensive Psychiatry</i> , 2014, 55, 1726-1729.	1.5	54
57	Fluoxetine in the Prevention of Depressive Recurrences: A Double-Blind Study. <i>Journal of Clinical Psychopharmacology</i> , 2001, 21, 417-424.	0.7	52
58	BDNF and NGF Signalling in Early Phases of Psychosis: Relationship With Inflammation and Response to Antipsychotics After 1 Year. <i>Schizophrenia Bulletin</i> , 2016, 42, sbv078.	2.3	52
59	A common variant in DRD3 gene is associated with risperidone-induced extrapyramidal symptoms. <i>Pharmacogenomics Journal</i> , 2009, 9, 404-410.	0.9	50
60	Prevalence and awareness of cardiovascular risk factors in patients with schizophrenia: A cross-sectional study in a low cardiovascular disease risk geographical area. <i>European Psychiatry</i> , 2009, 24, 431-441.	0.1	50
61	Validation of the Spanish version of the Clinical Assessment for Negative Symptoms (CAINS). <i>Schizophrenia Research</i> , 2015, 166, 104-109.	1.1	50
62	Evolution of metabolic risk factors over a two-year period in a cohort of first episodes of psychosis. <i>Schizophrenia Research</i> , 2018, 193, 188-196.	1.1	50
63	The course of negative symptoms in first-episode schizophrenia and its predictors: A prospective two-year follow-up study. <i>Schizophrenia Research</i> , 2017, 189, 84-90.	1.1	49
64	Neurotoxic/neuroprotective activity of haloperidol, risperidone and paliperidone in neuroblastoma cells. <i>Progress in Neuro-Psychopharmacology and Biological Psychiatry</i> , 2012, 36, 71-77.	2.5	47
65	Consenso español sobre los riesgos y detección de la hiperprolactinemia iatrogénica por antipsicóticos. <i>Revista De Psiquiatría Y Salud Mental</i> , 2016, 9, 158-173.	1.0	47
66	Multidisciplinary consensus on the therapeutic recommendations for iatrogenic hyperprolactinemia secondary to antipsychotics. <i>Frontiers in Neuroendocrinology</i> , 2017, 45, 25-34.	2.5	46
67	Estimating Exposome Score for Schizophrenia Using Predictive Modeling Approach in Two Independent Samples: The Results From the EUGEI Study. <i>Schizophrenia Bulletin</i> , 2019, 45, 960-965.	2.3	46
68	Dopamine transporter (DAT) genotype (VNTR) and phenotype in extrapyramidal symptoms induced by antipsychotics. <i>Schizophrenia Research</i> , 2007, 90, 115-122.	1.1	45
69	Increased susceptibility to apoptosis in cultured fibroblasts from antipsychotic-naïve first-episode schizophrenia patients. <i>Journal of Psychiatric Research</i> , 2014, 48, 94-101.	1.5	45
70	Suicidal Ideation, Psychiatric Disorder, and Medical Illness in a Community Epidemiological Study. <i>Suicide and Life-Threatening Behavior</i> , 2001, 31, 207-213.	0.9	44
71	Brief cognitive assessment instruments in schizophrenia and bipolar patients, and healthy control subjects: A comparison study between the Brief Cognitive Assessment Tool for Schizophrenia (B-CATS) and the Screen for Cognitive Impairment in Psychiatry (SCIP). <i>Schizophrenia Research</i> , 2011, 130, 137-142.	1.1	44
72	Factors associated with relapse in patients with schizophrenia. <i>International Journal of Psychiatry in Clinical Practice</i> , 2013, 17, 2-9.	1.2	44

#	ARTICLE	IF	CITATIONS
73	Modelling gene-environment interaction in first episodes of psychosis. <i>Schizophrenia Research</i> , 2017, 189, 181-189.	1.1	43
74	Polymorphism of dopamine D2 receptor (TaqIA, TaqIB, and-141C Ins/Del) and dopamine degradation enzyme (COMT G158A, A-278G) genes and extrapyramidal symptoms in patients with schizophrenia and bipolar disorders. <i>Psychiatry Research</i> , 2008, 161, 131-141.	1.7	42
75	Protocol for the management of psychiatric patients with psychomotor agitation. <i>BMC Psychiatry</i> , 2017, 17, 328.	1.1	42
76	Cannabis use and age of diagnosis of schizophrenia. <i>European Psychiatry</i> , 2009, 24, 282-286.	0.1	41
77	Neutrophil Count Is Associated With Reduced Gray Matter and Enlarged Ventricles in First-Episode Psychosis. <i>Schizophrenia Bulletin</i> , 2019, 45, 846-858.	2.3	41
78	The EUropean Network of National Schizophrenia Networks Studying Gene-Environment Interactions (EU-GEI): Incidence and First-Episode Case-Control Programme. <i>Social Psychiatry and Psychiatric Epidemiology</i> , 2020, 55, 645-657.	1.6	41
79	The resting and activation issue of hypofrontality: a single photon emission computed tomography study in neuroleptic-naive and neuroleptic-free schizophrenic female patients. <i>Biological Psychiatry</i> , 1998, 44, 787-790.	0.7	40
80	Decreased striatal dopamine transporter binding assessed with [123I] FP-CIT in first-episode schizophrenic patients with and without short-term antipsychotic-induced parkinsonism. <i>Psychopharmacology</i> , 2005, 181, 401-406.	1.5	40
81	Is cognitive impairment associated with antipsychotic dose and anticholinergic equivalent loads in first-episode psychosis?. <i>Psychological Medicine</i> , 2018, 48, 2247-2256.	2.7	40
82	Metabolic Effects of Olanzapine in Patients With Newly Diagnosed Psychosis. <i>Journal of Clinical Psychopharmacology</i> , 2011, 31, 154-159.	0.7	39
83	Cerebellar deficits in schizophrenia are associated with executive dysfunction. <i>NeuroReport</i> , 2008, 19, 1513-1517.	0.6	38
84	Insertion/deletion polymorphism of the angiotensin-converting enzyme gene is associated with schizophrenia in a Spanish population. <i>Psychiatry Research</i> , 2009, 165, 175-180.	1.7	38
85	Testosterone in Newly Diagnosed, Antipsychotic-Naive Men With Nonaffective Psychosis. <i>Psychosomatic Medicine</i> , 2011, 73, 643-647.	1.3	38
86	Antipsychotic Response Worsens With Postmenopausal Duration in Women With Schizophrenia. <i>Journal of Clinical Psychopharmacology</i> , 2016, 36, 580-587.	0.7	38
87	Clinical, Cognitive, and Neuroimaging Evidence of a Neurodevelopmental Continuum in Offspring of Proband With Schizophrenia and Bipolar Disorder. <i>Schizophrenia Bulletin</i> , 2017, 43, 1208-1219.	2.3	38
88	Distinct risk factors for obsessive and compulsive symptoms in chronic schizophrenia. <i>Psychological Medicine</i> , 2018, 48, 2668-2675.	2.7	38
89	Daily use of high-potency cannabis is associated with more positive symptoms in first-episode psychosis patients: the EU-GEI case-control study. <i>Psychological Medicine</i> , 2021, 51, 1329-1337.	2.7	38
90	Schizophrenia and frontal cortex: Where does it fail?. <i>Schizophrenia Research</i> , 2007, 91, 73-81.	1.1	37

#	ARTICLE	IF	CITATIONS
91	Clinical usefulness of the screen for cognitive impairment in psychiatry (SCIP-S) scale in patients with type I bipolar disorder. <i>Health and Quality of Life Outcomes</i> , 2009, 7, 28.	1.0	37
92	The screen for cognitive impairment in psychiatry: diagnostic-specific standardization in psychiatric ill patients. <i>BMC Psychiatry</i> , 2013, 13, 127.	1.1	37
93	Cuando la asistencia no sigue a la evidencia: el caso de la falta de programas de intervenci3n temprana en psicosis en Espa1a. <i>Revista De Psiquiatr3a Y Salud Mental</i> , 2017, 10, 78-86.	1.0	37
94	Left posterior hippocampal density reduction using VBM and stereological MRI procedures in schizophrenia. <i>Schizophrenia Research</i> , 2007, 96, 62-71.	1.1	36
95	CYP2D6*3, *4, *5 AND *6 POLYMORPHISMS AND ANTIPSYCHOTIC-INDUCED EXTRAPYRAMIDAL SIDE-EFFECTS IN PATIENTS RECEIVING ANTIPSYCHOTIC THERAPY. <i>Clinical and Experimental Pharmacology and Physiology</i> , 2008, 35, 807-811.	0.9	36
96	Replication of previous genome-wide association studies of psychiatric diseases in a large schizophrenia case-control sample from Spain. <i>Schizophrenia Research</i> , 2014, 159, 107-113.	1.1	36
97	Cognition and psychopathology in first-episode psychosis: are they related to inflammation?. <i>Psychological Medicine</i> , 2016, 46, 2133-2144.	2.7	36
98	Examining the independent and joint effects of genomic and exposomic liabilities for schizophrenia across the psychosis spectrum. <i>Epidemiology and Psychiatric Sciences</i> , 2020, 29, e182.	1.8	36
99	Absence of Additional Cognitive Impairment in Schizophrenia Patients During Maintenance Electroconvulsive Therapy. <i>Schizophrenia Bulletin</i> , 2004, 30, 185-189.	2.3	35
100	The effect of quetiapine on aggression and hostility in patients with schizophrenia. <i>Human Psychopharmacology</i> , 2005, 20, 237-241.	0.7	35
101	Clinical Experience Using Electroconvulsive Therapy in Adolescents with Schizophrenia Spectrum Disorders. <i>Journal of Child and Adolescent Psychopharmacology</i> , 2010, 20, 205-209.	0.7	35
102	Intuitive pharmacogenetics: spontaneous risperidone dosage is related to CYP2D6, CYP3A5 and ABCB1 genotypes. <i>Pharmacogenomics Journal</i> , 2012, 12, 255-259.	0.9	35
103	Disability in bipolar I disorder: The 36-item World Health Organization Disability Assessment Schedule 2.0. <i>Journal of Affective Disorders</i> , 2015, 174, 353-360.	2.0	35
104	Una d3cada del proyecto de primeros episodios psic3ticos (PEPs): avanzando hacia una psiquiatr3a de precisi3n. <i>Revista De Psiquiatr3a Y Salud Mental</i> , 2019, 12, 135-140.	1.0	35
105	Jumping to conclusions, general intelligence, and psychosis liability: findings from the multi-centre EU-GEI case-control study. <i>Psychological Medicine</i> , 2021, 51, 623-633.	2.7	34
106	Topiramate for Clozapine-Induced Seizures. <i>American Journal of Psychiatry</i> , 2001, 158, 968-a-969.	4.0	34
107	A voxel-based diffusion tensor imaging study of temporal white matter in patients with schizophrenia. <i>Psychiatry Research - Neuroimaging</i> , 2009, 171, 166-176.	0.9	33
108	Two-Year Follow-Up of Cognitive Functions in Schizophrenia Spectrum Disorders of Adolescent Patients Treated with Electroconvulsive Therapy. <i>Journal of Child and Adolescent Psychopharmacology</i> , 2011, 21, 611-619.	0.7	33



#	ARTICLE	IF	CITATIONS
109	Antipsychotic polypharmacy in a regional health service: a population-based study. <i>BMC Psychiatry</i> , 2012, 12, 42.	1.1	32
110	The thrifty psychiatric phenotype. <i>Acta Psychiatrica Scandinavica</i> , 2015, 131, 18-20.	2.2	32
111	Neuroimaging studies of cognitive remediation in schizophrenia: A systematic and critical review. <i>World Journal of Psychiatry</i> , 2017, 7, 34.	1.3	32
112	Examining Gene-Environment Interactions Using Aggregate Scores in a First-Episode Psychosis Cohort. <i>Schizophrenia Bulletin</i> , 2020, 46, 1019-1025.	2.3	32
113	Individual trajectories of cognitive performance in first episode psychosis: a 2-year follow-up study. <i>European Archives of Psychiatry and Clinical Neuroscience</i> , 2018, 268, 699-711.	1.8	31
114	Cognitive Reserve Assessment Scale in Health (CRASH): Its Validity and Reliability. <i>Journal of Clinical Medicine</i> , 2019, 8, 586.	1.0	31
115	Influence of social cognition as a mediator between cognitive reserve and psychosocial functioning in patients with first episode psychosis. <i>Psychological Medicine</i> , 2020, 50, 2702-2710.	2.7	31
116	Frontal Cerebral Perfusion After Antidepressant Drug Treatment Versus ECT in Elderly Patients With Major Depression. <i>Journal of Clinical Psychiatry</i> , 2004, 65, 656-661.	1.1	31
117	Processing speed and executive functions predict real-world everyday living skills in adolescents with early-onset schizophrenia. <i>European Child and Adolescent Psychiatry</i> , 2012, 21, 315-326.	2.8	30
118	Pharmacogenetic predictor of extrapyramidal symptoms induced by antipsychotics: Multilocus interaction in the mTOR pathway. <i>European Neuropsychopharmacology</i> , 2015, 25, 51-59.	0.3	30
119	Apoptotic markers in cultured fibroblasts correlate with brain metabolites and regional brain volume in antipsychotic-naïve first-episode schizophrenia and healthy controls. <i>Translational Psychiatry</i> , 2015, 5, e626-e626.	2.4	30
120	Pharmacogenetic study of antipsychotic induced acute extrapyramidal symptoms in a first episode psychosis cohort: role of dopamine, serotonin and glutamate candidate genes. <i>Pharmacogenomics Journal</i> , 2016, 16, 439-445.	0.9	30
121	Fluorodeoxyglucose-PET study in first-episode schizophrenic patients during the hallucinatory state, after remission and during linguistic auditory activation. <i>Nuclear Medicine Communications</i> , 2008, 29, 894-900.	0.5	29
122	18FDG PET study of amygdalar activity during facial emotion recognition in schizophrenia. <i>European Archives of Psychiatry and Clinical Neuroscience</i> , 2010, 260, 69-76.	1.8	29
123	Differential brain glucose metabolic patterns in antipsychotic-naïve first-episode schizophrenia with and without auditory verbal hallucinations. <i>Journal of Psychiatry and Neuroscience</i> , 2011, 36, 312-321.	1.4	29
124	Electroconvulsive Therapy and Clozapine in Adolescents With Schizophrenia Spectrum Disorders. <i>Journal of Clinical Psychopharmacology</i> , 2012, 32, 756-766.	0.7	29
125	Screening for substance use disorders in first-episode psychosis: Implications for readmission. <i>Schizophrenia Research</i> , 2013, 146, 125-131.	1.1	29
126	A Pharmacovigilance Study in First Episode of Psychosis: Psychopharmacological Interventions and Safety Profiles in the PEPs Project. <i>International Journal of Neuropsychopharmacology</i> , 2016, 19, pyv121.	1.0	29



#	ARTICLE	IF	CITATIONS
127	Double-blind olanzapine vs. haloperidol D2 dopamine receptor blockade in schizophrenic patients: a baseline-endpoint [ <sup>123</sup> I]IBZM SPECT study. <i>Psychiatry Research - Neuroimaging</i> , 2001, 107, 87-97.	0.9	28
128	Basal ganglia N-acetylaspartate correlates with the performance in the procedural task "Tower of Hanoi" of neuroleptic-naive schizophrenic patients. <i>Neuroscience Letters</i> , 2003, 347, 97-100.	1.0	28
129	Hippocampal abnormalities and age in chronic schizophrenia: morphometric study across the adult lifespan. <i>British Journal of Psychiatry</i> , 2014, 205, 369-375.	1.7	28
130	The search for new biomarkers for cognition in schizophrenia. <i>Schizophrenia Research: Cognition</i> , 2015, 2, 172-178.	0.7	28
131	Blood cell count in antipsychotic-naive patients with non-affective psychosis. <i>Microbial Biotechnology</i> , 2019, 13, 95-100.	0.9	28
132	Replicated evidence that endophenotypic expression of schizophrenia polygenic risk is greater in healthy siblings of patients compared to controls, suggesting gene-environment interaction. The EUGEL study. <i>Psychological Medicine</i> , 2020, 50, 1884-1897.	2.7	28
133	Seizure Activity and Safety in Combined Treatment with Venlafaxine and ECT: A Pilot Study. <i>Journal of ECT</i> , 2000, 16, 38-42.	0.3	28
134	Persistent Negative Symptoms in First-Episode Psychosis. <i>Journal of Clinical Psychiatry</i> , 2017, 78, 1414-1422.	1.1	28
135	Pattern of cognitive dysfunction in depressive patients during maintenance electroconvulsive therapy. <i>Psychological Medicine</i> , 2003, 33, 345-350.	2.7	27
136	¿QuÃ© hemos aprendido de la investigaci3n en primeros episodios psic3ticos?. <i>Revista De PsiquiatrÃa Y Salud Mental</i> , 2014, 7, 61-63.	1.0	27
137	Clozapine and paliperidone palmitate antipsychotic combination in treatment-resistant schizophrenia and other psychotic disorders: A retrospective 6-month mirror-image study. <i>European Psychiatry</i> , 2020, 63, e71.	0.1	27
138	Role of the cingulate gyrus during the Wisconsin Card Sorting Test: a single photon emission computed tomography study in normal volunteers. <i>Psychiatry Research - Neuroimaging</i> , 1998, 83, 67-74.	0.9	26
139	Mental disorders on the island of Formentera: prevalence in general population using the Schedules for Clinical Assessment in Neuropsychiatry (SCAN). <i>Social Psychiatry and Psychiatric Epidemiology</i> , 1999, 34, 410-415.	1.6	26
140	Recomendaciones para el cambio de antipsic3ticos. Posicionamiento de la Sociedad EspaÃ±ola de PsiquiatrÃa y Sociedad EspaÃ±ola de PsiquiatrÃa Biol3gica. <i>Revista De PsiquiatrÃa Y Salud Mental</i> , 2011, 4, 150-168.	1.0	26
141	Comparison between young siblings and offspring of subjects with schizophrenia: Clinical and neuropsychological characteristics. <i>Schizophrenia Research</i> , 2011, 131, 35-42.	1.1	26
142	Pro-/Antiinflammatory Dysregulation in Early Psychosis: Results from a 1-Year Follow-Up Study. <i>International Journal of Neuropsychopharmacology</i> , 2015, 18, pyu037-pyu037.	1.0	26
143	Electroconvulsive Therapy Practice in Spain. <i>Journal of ECT</i> , 2016, 32, 55-61.	0.3	26
144	Cortical thickness in regions of frontal and temporal lobes is associated with responsiveness to cognitive remediation therapy in schizophrenia. <i>Schizophrenia Research</i> , 2016, 171, 110-116.	1.1	26

#	ARTICLE	IF	CITATIONS
145	Cannabis use, COMT, BDNF and age at first-episode psychosis. <i>Psychiatry Research</i> , 2017, 250, 38-43.	1.7	26
146	Affective versus non-affective first episode psychoses: A longitudinal study. <i>Journal of Affective Disorders</i> , 2018, 238, 297-304.	2.0	26
147	Spanish adaptation of the Beck Cognitive Insight Scale (BCIS) for schizophrenia. <i>Actas Espanolas De Psiquiatria</i> , 2012, 40, 2-9.	0.1	26
148	A prospective, multicentre, open-label study of aripiprazole in the management of patients with schizophrenia in psychiatric practice in Europe: Broad Effectiveness Trial with Aripiprazole in Europe (EU-BETA). <i>Current Medical Research and Opinion</i> , 2007, 23, 2313-2323.	0.9	25
149	-141C Ins/Del polymorphism of the dopamine D2 receptor gene is associated with schizophrenia in a Spanish population. <i>Psychiatric Genetics</i> , 2008, 18, 122-127.	0.6	25
150	Brain Metabolism during Hallucination-Like Auditory Stimulation in Schizophrenia. <i>PLoS ONE</i> , 2014, 9, e84987.	1.1	25
151	Antipsychotic switching in bipolar disorders: a systematic review. <i>International Journal of Neuropsychopharmacology</i> , 2014, 17, 497-507.	1.0	25
152	Inverse association between negative symptoms and body mass index in chronic schizophrenia. <i>Schizophrenia Research</i> , 2018, 192, 69-74.	1.1	25
153	Real-World Data on the Adverse Metabolic Effects of Second-Generation Antipsychotics and Their Potential Determinants in Adult Patients: A Systematic Review of Population-Based Studies. <i>Advances in Therapy</i> , 2021, 38, 2491-2512.	1.3	25
154	Cognitive Status of Psychiatric Patients Under Maintenance Electroconvulsive Therapy: A One-Year Longitudinal Study. <i>Journal of Neuropsychiatry and Clinical Neurosciences</i> , 2004, 16, 465-471.	0.9	24
155	Assessing clinical and functional outcomes in a gene-environment interaction study in first episode of psychosis (PEPs). <i>Revista De Psiquiatria Y Salud Mental (English Edition)</i> , 2013, 6, 4-16.	0.2	24
156	Dignificando una terapia electroconvulsiva basada en la evidencia. <i>Revista De Psiquiatria Y Salud Mental</i> , 2015, 8, 51-54.	1.0	24
157	Electroconvulsive therapy protocol adaptation during the COVID-19 pandemic. <i>Journal of Affective Disorders</i> , 2020, 276, 241-248.	2.0	24
158	Oxcarbazepine in the treatment of bipolar and schizoaffective disorders. <i>Expert Review of Neurotherapeutics</i> , 2007, 7, 617-626.	1.4	23
159	SIMULTANEOUS GENOTYPING OF CYP2D6*3, *4, *5 AND *6 POLYMORPHISMS IN A SPANISH POPULATION THROUGH MULTIPLEX LONG POLYMERASE CHAIN REACTION AND MINISEQUENCING MULTIPLEX SINGLE BASE EXTENSION ANALYSIS. <i>Clinical and Experimental Pharmacology and Physiology</i> , 2007, 34, 992-997.	0.9	23
160	Spanish consensus on the risks and detection of antipsychotic drug-related hyperprolactinaemia. <i>Revista De Psiquiatria Y Salud Mental (English Edition)</i> , 2016, 9, 158-173.	0.2	23
161	Antipsicóticos inyectables de liberación prolongada para el tratamiento de la esquizofrenia en España. <i>Revista De Psiquiatria Y Salud Mental</i> , 2019, 12, 92-105.	1.0	23
162	Cognitive functioning throughout adulthood and illness stages in individuals with psychotic disorders and their unaffected siblings. <i>Molecular Psychiatry</i> , 2021, 26, 4529-4543.	4.1	23

#	ARTICLE	IF	CITATIONS
163	Cost-Effectiveness Analysis of Schizophrenia Relapse Prevention. <i>Clinical Drug Investigation</i> , 2006, 26, 447-457.	1.1	22
164	Socio-demographic, clinical and treatment characteristics of relapsing schizophrenic patients. <i>Nordic Journal of Psychiatry</i> , 2013, 67, 22-29.	0.7	22
165	Metabolic syndrome or glucose challenge in first episode of psychosis?. <i>European Psychiatry</i> , 2017, 41, 42-46.	0.1	22
166	Effects of electroconvulsive therapy in the systemic inflammatory balance of patients with severe mental disorder. <i>Psychiatry and Clinical Neurosciences</i> , 2019, 73, 628-635.	1.0	22
167	Migration history and risk of psychosis: results from the multinational EU-GEI study. <i>Psychological Medicine</i> , 2022, 52, 2972-2984.	2.7	22
168	Opposite Cannabis-Cognition Associations in Psychotic Patients Depending on Family History. <i>PLoS ONE</i> , 2016, 11, e0160949.	1.1	22
169	Lack of sex differences in striatal dopamine D2 receptor binding in drug-naive schizophrenic patients: an IBZM-SPECT study. <i>Psychiatry Research - Neuroimaging</i> , 2004, 130, 79-84.	0.9	21
170	Association of A/G Polymorphism in Intron 13 of the Monoamine Oxidase B Gene with Schizophrenia in a Spanish Population. <i>Neuropsychobiology</i> , 2008, 58, 65-70.	0.9	21
171	Relationship between clinical and neuropsychological characteristics in child and adolescent first degree relatives of subjects with schizophrenia. <i>Schizophrenia Research</i> , 2010, 116, 159-167.	1.1	21
172	Anterior cingulate and paracingulate sulci morphology in patients with schizophrenia. <i>Schizophrenia Research</i> , 2010, 121, 66-74.	1.1	21
173	<scp>QTc</scp> prolongation: is clozapine safe? Study of 82 cases before and after clozapine treatment. <i>Human Psychopharmacology</i> , 2011, 26, 397-403.	0.7	21
174	Effectiveness of long-acting injectable antipsychotics in delusional disorders with nonprominent hallucinations and without hallucinations. <i>International Clinical Psychopharmacology</i> , 2014, 29, 177-180.	0.9	21
175	The functioning assessment short test (FAST) applied to first-episode psychosis: Psychometric properties and severity thresholds. <i>European Neuropsychopharmacology</i> , 2021, 47, 98-111.	0.3	21
176	Cotard's Syndrome in a Young Male Bipolar Patient. <i>Journal of Neuropsychiatry and Clinical Neurosciences</i> , 2000, 12, 117-120.	0.9	20
177	Sulforaphane protects SKâ€œNâ€œSH cells against antipsychoticâ€œinduced oxidative stress. <i>Fundamental and Clinical Pharmacology</i> , 2012, 26, 712-721.	1.0	20
178	Identifying clinical clusters with distinct trajectories in first-episode psychosis through an unsupervised machine learning technique. <i>European Neuropsychopharmacology</i> , 2021, 47, 112-129.	0.3	20
179	Brain perfusion and neuropsychological changes in schizophrenic patients after cognitive rehabilitation. <i>Psychiatry Research - Neuroimaging</i> , 2000, 98, 127-132.	0.9	19
180	Stem cell signaling in newly diagnosed, antipsychotic-naive subjects with nonaffective psychosis. <i>Molecular Psychiatry</i> , 2009, 14, 989-991.	4.1	19

#	ARTICLE	IF	CITATIONS
181	Use of Electroconvulsive Therapy in Parkinson Disease With Residual Axial Symptoms Partially Unresponsive to L-Dopa. <i>Journal of ECT</i> , 2012, 28, 87-91.	0.3	19
182	Inferior frontal and insular cortical thinning is related to dysfunctional brain activation/deactivation during working memory task in schizophrenic patients. <i>Psychiatry Research - Neuroimaging</i> , 2013, 214, 94-101.	0.9	19
183	Secondary nonmotor negative symptoms in healthy volunteers after single doses of haloperidol and risperidone: a double-blind, crossover, placebo-controlled trial. <i>Human Psychopharmacology</i> , 2013, 28, 586-593.	0.7	19
184	Profile of paliperidone palmitate once-monthly long-acting injectable in the management of schizophrenia: long-term safety, efficacy, and patient acceptability – a review. <i>Patient Preference and Adherence</i> , 2015, 9, 695.	0.8	19
185	BDNF as a marker of response to cognitive remediation in patients with schizophrenia: A randomized and controlled trial. <i>Schizophrenia Research</i> , 2018, 197, 458-464.	1.1	19
186	Striatal dopamine D2 receptor density in neuroleptic-naive and in neuroleptic-free schizophrenic patients: an 123 I-BZM-SPECT study. <i>Psychopharmacology</i> , 2004, 172, 165-169.	1.5	18
187	Hippocampal underactivation in an fMRI study of word and face memory recognition in schizophrenia. <i>European Archives of Psychiatry and Clinical Neuroscience</i> , 2009, 259, 203-211.	1.8	18
188	Network analysis of gene expression in peripheral blood identifies mTOR and NF- $\kappa$ B pathways involved in antipsychotic-induced extrapyramidal symptoms. <i>Pharmacogenomics Journal</i> , 2015, 15, 452-460.	0.9	18
189	The negative syndrome of schizophrenia: Three underlying components are better than two. <i>Schizophrenia Research</i> , 2015, 166, 115-118.	1.1	18
190	Dysregulated peripheral endocannabinoid system signaling is associated with cognitive deficits in first-episode psychosis. <i>Journal of Psychiatric Research</i> , 2016, 75, 14-21.	1.5	18
191	Eficacia, eficiencia y efectividad en el tratamiento multidimensional de la esquizofrenia: proyecto Rethinking. <i>Revista De Psiquiatría Y Salud Mental</i> , 2017, 10, 4-20.	1.0	18
192	Obstetric Phenotypes in the Heterogeneity of Schizophrenia. <i>Journal of Nervous and Mental Disease</i> , 2018, 206, 882-886.	0.5	18
193	Examining the association between exposome score for schizophrenia and functioning in schizophrenia, siblings, and healthy controls: Results from the EUGEI study. <i>European Psychiatry</i> , 2021, 64, e25.	0.1	18
194	Two Factors, Five Factors, or Both? External Validation Studies of Negative Symptom Dimensions in Schizophrenia. <i>Schizophrenia Bulletin</i> , 2022, 48, 620-630.	2.3	18
195	Antidepressant-induced mania in obsessive-compulsive disorder. <i>American Journal of Psychiatry</i> , 1992, 149, 1282-3.	4.0	18
196	Adaptation and validation of the quality-of-life scale: Satisfaction with Life Domains Scale by Baker and Intagliata. <i>Comprehensive Psychiatry</i> , 2009, 50, 76-80.	1.5	17
197	Plasma homovanillic acid differences in clinical subgroups of first episode schizophrenic patients. <i>Psychiatry Research</i> , 2009, 168, 110-118.	1.7	17
198	Lack of association between antipsychotic-induced extrapyramidal symptoms and polymorphisms in dopamine metabolism and transport genes. <i>Psychiatry Research</i> , 2010, 175, 173-175.	1.7	17

#	ARTICLE	IF	CITATIONS
199	Strengths and weaknesses of pharmacogenetic studies of antipsychotic drugs: the potential value of the PEPs study. <i>Pharmacogenomics</i> , 2012, 13, 1773-1782.	0.6	17
200	Functional analysis of gene expression in risperidone treated cells provide new insights in molecular mechanism and new candidate genes for pharmacogenetic studies. <i>European Neuropsychopharmacology</i> , 2013, 23, 329-337.	0.3	17
201	Comparison of serum BDNF levels in deficit and nondeficit chronic schizophrenia and healthy controls. <i>Psychiatry Research</i> , 2014, 220, 197-200.	1.7	17
202	Association of the <i>brain-derived neurotrophic factor</i> Val66Met polymorphism with negative symptoms severity, but not cognitive function, in first-episode schizophrenia spectrum disorders. <i>European Psychiatry</i> , 2016, 38, 61-69.	0.1	17
203	Antipsychotic switching in schizoaffective disorder: A systematic review. <i>World Journal of Biological Psychiatry</i> , 2016, 17, 495-513.	1.3	17
204	The impact of cognitive reserve, cognition and clinical symptoms on psychosocial functioning in first-episode psychoses. <i>Psychological Medicine</i> , 2022, 52, 526-537.	2.7	17
205	The incidence of psychotic disorders among migrants and minority ethnic groups in Europe: findings from the multinational EU-GEI study. <i>Psychological Medicine</i> , 2022, 52, 1376-1385.	2.7	17
206	Trajectories of suicidal ideation after first-episode psychosis: a growth mixture modeling approach. <i>Acta Psychiatrica Scandinavica</i> , 2021, 143, 418-433.	2.2	17
207	The Independent Effects of Psychosocial Stressors on Subclinical Psychosis: Findings From the Multinational EU-GEI Study. <i>Schizophrenia Bulletin</i> , 2021, 47, 1674-1684.	2.3	17
208	Predictors of Bipolar Disorder Versus Schizophrenia Diagnosis in a Multicenter First Psychotic Episode Cohort. <i>Journal of Clinical Psychiatry</i> , 2020, 81, .	1.1	17
209	Relapse and therapeutic interventions in a 1-year observational cohort study of nonadherent outpatients with schizophrenia. <i>Progress in Neuro-Psychopharmacology and Biological Psychiatry</i> , 2012, 36, 245-250.	2.5	16
210	Relationship between <i>CYP2D6</i> genotype and haloperidol pharmacokinetics and extrapyramidal symptoms in healthy volunteers. <i>Pharmacogenomics</i> , 2013, 14, 1551-1563.	0.6	16
211	¿Es bipolar disorder an endocrine condition? Glucose abnormalities in bipolar disorder. <i>Acta Psychiatrica Scandinavica</i> , 2014, 129, 73-74.	2.2	16
212	La adherencia predice la remisión sintomática y psicosocial en esquizofrenia: estudio naturalístico de la integración de los pacientes en la comunidad. <i>Revista De Psiquiatría Y Salud Mental</i> , 2017, 10, 149-159.	1.0	16
213	Gene-environment interaction between an endocannabinoid system genetic polymorphism and cannabis use in first episode of psychosis. <i>European Neuropsychopharmacology</i> , 2019, 29, 786-794.	0.3	16
214	ARVCF single marker and haplotypic association with schizophrenia. <i>Progress in Neuro-Psychopharmacology and Biological Psychiatry</i> , 2009, 33, 1064-1069.	2.5	15
215	Patients' Opinions About Electroconvulsive Therapy: What Do Adolescents with Schizophrenia Spectrum Disorders Think?. <i>Journal of Child and Adolescent Psychopharmacology</i> , 2015, 25, 641-648.	0.7	15
216	Antipsychotic-induced weight gain and birth weight in psychosis: A fetal programming model. <i>Journal of Psychiatric Research</i> , 2019, 115, 29-35.	1.5	15

#	ARTICLE	IF	CITATIONS
217	Double-Blind, Placebo-Controlled Study of the Efficacy of Reboxetine and Citalopram as Adjuncts to Atypical Antipsychotics for Negative Symptoms of Schizophrenia. <i>Journal of Clinical Psychiatry</i> , 2014, 75, 608-615.	1.1	15
218	Clinical and treatment predictors of relapse during a three-year follow-up of a cohort of first episodes of schizophrenia. <i>Schizophrenia Research</i> , 2022, 243, 32-42.	1.1	15
219	Psychopathology and Wisconsin Card Sorting Test Performance in Young Unmedicated Schizophrenic Patients. <i>Psychopathology</i> , 2000, 33, 14-18.	1.1	14
220	Ziprasidone Overdose: Cases Recorded in the Database of Pfizer-Spain and Literature Review. <i>Pharmacotherapy</i> , 2005, 25, 1660-1665.	1.2	14
221	Cognitive functions after only one ECT session: A controlled study. <i>Psychiatry Research</i> , 2008, 158, 389-394.	1.7	14
222	Effect of CYP2D6 on risperidone pharmacokinetics and extrapyramidal symptoms in healthy volunteers: results from a pharmacogenetic clinical trial. <i>Pharmacogenomics</i> , 2014, 15, 17-28.	0.6	14
223	Long-term effectiveness of electroconvulsive therapy in adolescents with schizophrenia spectrum disorders. <i>European Child and Adolescent Psychiatry</i> , 2015, 24, 517-524.	2.8	14
224	Do FSH/LH ratio and gonadal hormone levels predict clinical improvement in postmenopausal schizophrenia women?. <i>Archives of Women's Mental Health</i> , 2017, 20, 613-620.	1.2	14
225	Premorbid Adjustment and IQ in Patients With First-Episode Psychosis: A Multisite Case-Control Study of Their Relationship With Cannabis Use. <i>Schizophrenia Bulletin</i> , 2020, 46, 517-529.	2.3	14
226	Evidence, and replication thereof, that molecular-genetic and environmental risks for psychosis impact through an affective pathway. <i>Psychological Medicine</i> , 2022, 52, 1910-1922.	2.7	14
227	Brain structural trajectories in youth at familial risk for schizophrenia or bipolar disorder according to development of psychosis spectrum symptoms. <i>Journal of Child Psychology and Psychiatry and Allied Disciplines</i> , 2021, 62, 780-789.	3.1	14
228	Exploring Risk and Resilient Profiles for Functional Impairment and Baseline Predictors in a 2-Year Follow-Up First-Episode Psychosis Cohort Using Latent Class Growth Analysis. <i>Journal of Clinical Medicine</i> , 2021, 10, 73.	1.0	14
229	Positive versus negative symptoms in schizophrenia: Response to haloperidol. <i>Progress in Neuro-Psychopharmacology and Biological Psychiatry</i> , 1994, 18, 155-164.	2.5	13
230	No Brain Perfusion Impairment at Long-term Follow-up In Elderly Patients Treated With Electroconvulsive Therapy for Major Depression. <i>Journal of ECT</i> , 2004, 20, 89-93.	0.3	13
231	Network analysis of gene expression in mice provides new evidence of involvement of the mTOR pathway in antipsychotic-induced extrapyramidal symptoms. <i>Pharmacogenomics Journal</i> , 2016, 16, 293-300.	0.9	13
232	Gene-environment interaction as a predictor of early adjustment in first episode psychosis. <i>Schizophrenia Research</i> , 2017, 189, 196-203.	1.1	13
233	Intuitive pharmacogenetic dosing of risperidone according to CYP2D6 phenotype extrapolated from genotype in a cohort of first episode psychosis patients. <i>European Neuropsychopharmacology</i> , 2017, 27, 647-656.	0.3	13
234	Smoking does not impact social and non-social cognition in patients with first episode psychosis. <i>Schizophrenia Research</i> , 2018, 199, 64-74.	1.1	13



#	ARTICLE	IF	CITATIONS
235	Indicadores de calidad en el tratamiento de pacientes con depresi3n, trastorno bipolar o esquizofrenia. Estudio de consenso. Revista De Psiquiatr3a Y Salud Mental, 2018, 11, 66-75.	1.0	13
236	Cardiovascular Risk in Early Psychosis: Relationship with Inflammation and Clinical Features 6 Months after Diagnosis. International Journal of Neuropsychopharmacology, 2018, 21, 410-422.	1.0	13
237	The prevention of relapses in first episodes of schizophrenia: The 2EPs Project, background, rationale and study design. Revista De Psiquiatr3a Y Salud Mental, 2021, 14, 164-176.	1.0	13
238	Antipsychotic response in delusional disorder and schizophrenia: a prospective cohort study. Actas Espanolas De Psiquiatria, 2016, 44, 125-35.	0.1	13
239	Mental disorders and medical conditions. Journal of Psychosomatic Research, 2001, 50, 39-44.	1.2	12
240	Comparative Hemodynamic Effects of Urapidil and Labetalol After Electroconvulsive Therapy. Journal of ECT, 2001, 17, 275-279.	0.3	12
241	Xenobiotic metabolizing and transporter genes: gene-gene interactions in schizophrenia and related disorders. Pharmacogenomics, 2010, 11, 1725-1731.	0.6	12
242	Searching for functional SNPs or rare variants in exonic regions of DRD3 in risperidone-treated patients. European Neuropsychopharmacology, 2011, 21, 294-299.	0.3	12
243	Estudio retrospectivo del tratamiento y uso de consultas en un grupo cl3nico de pacientes con trastorno delirante. Revista De Psiquiatr3a Y Salud Mental, 2014, 7, 64-71.	1.0	12
244	Microarray gene-expression study in fibroblast and lymphoblastoid cell lines from antipsychotic-na3ve first-episode schizophrenia patients. Journal of Psychiatric Research, 2017, 95, 91-101.	1.5	12
245	Improving pharmacogenetic prediction of extrapyramidal symptoms induced by antipsychotics. Translational Psychiatry, 2018, 8, 276.	2.4	12
246	Association study of candidate genes with obesity and metabolic traits in antipsychotic-treated patients with first-episode psychosis over a 2-year period. Journal of Psychopharmacology, 2020, 34, 514-523.	2.0	12
247	The continuity of effect of schizophrenia polygenic risk score and patterns of cannabis use on transdiagnostic symptom dimensions at first-episode psychosis: findings from the EU-GEI study. Translational Psychiatry, 2021, 11, 423.	2.4	12
248	The effect of family environment and psychiatric family history on psychosocial functioning in first-episode psychosis at baseline and after 2 years. European Neuropsychopharmacology, 2021, 49, 54-68.	0.3	12
249	Psychopathological and nutritional correlates of plasma homovanillic acid in adolescents with anorexia nervosa. Journal of Psychiatric Research, 2008, 42, 213-220.	1.5	11
250	A 12-month, open-label, comparative study of quetiapine and risperidone in the acute and long-term treatment of schizophrenia. International Clinical Psychopharmacology, 2008, 23, 138-149.	0.9	11
251	Adaptaci3n y validaci3n espa3ola de la Escala Pron3stica para la Esquizofrenia de Strauss y Carpenter. Revista De Psiquiatr3a Y Salud Mental, 2009, 2, 150-159.	1.0	11
252	Electroconvulsive Therapy in Early Adolescents With Schizophrenia Spectrum Disorders. Journal of ECT, 2009, 25, 278-279.	0.3	11



#	ARTICLE	IF	CITATIONS
253	Lack of association between schizophrenia and polymorphisms in dopamine metabolism and transport genes. <i>Fundamental and Clinical Pharmacology</i> , 2010, 24, 741-747.	1.0	11
254	A 4-year dopamine transporter (DAT) imaging study in neuroleptic-naive first episode schizophrenia patients. <i>Psychiatry Research - Neuroimaging</i> , 2011, 194, 79-84.	0.9	11
255	The Integration of Cognitive Remediation Therapy into the Whole Psychosocial Rehabilitation Process: An Evidence-Based and Person-Centered Approach. <i>Rehabilitation Research and Practice</i> , 2012, 2012, 1-8.	0.5	11
256	Neuropsychological development in the child and adolescent offspring of patients diagnosed with schizophrenia or bipolar disorder: A two-year follow-up comparative study. <i>Progress in Neuro-Psychopharmacology and Biological Psychiatry</i> , 2020, 103, 109972.	2.5	11
257	Neuroleptic Malignant Syndrome Associated with Risperidone in a Male with Early-Onset Schizophrenia. <i>Journal of Child and Adolescent Psychopharmacology</i> , 2005, 15, 844-845.	0.7	10
258	A continuous emotional task activates the left amygdala in healthy volunteers: 18FDG PET study. <i>Psychiatry Research - Neuroimaging</i> , 2009, 171, 199-206.	0.9	10
259	Cholesterol and triglycerides in antipsychotic-naive patients with nonaffective psychosis. <i>Psychiatry Research</i> , 2010, 178, 559-561.	1.7	10
260	Delusional Disorder over the Reproductive Life Span: The Potential Influence of Menopause on the Clinical Course. <i>Schizophrenia Research and Treatment</i> , 2015, 2015, 1-8.	0.7	10
261	Association of birth weight and the development of antipsychotic induced adiposity in individuals with treatment resistant schizophrenia. <i>European Neuropsychopharmacology</i> , 2016, 26, 972-978.	0.3	10
262	PatrÃ³n de uso de la terapia electroconvulsiva en EspaÃ±a: propuestas para una prÃ¡ctica Ã³ptima y un acceso equitativo. <i>Revista De PsiquiatrÃ­a Y Salud Mental</i> , 2017, 10, 87-95.	1.0	10
263	The current data on the 3-month paliperidone palmitate formulation for the treatment of schizophrenia. <i>Expert Opinion on Pharmacotherapy</i> , 2018, 19, 1623-1629.	0.9	10
264	Early Parental Death and Risk of Psychosis in Offspring: A Six-Country Case-Control Study. <i>Journal of Clinical Medicine</i> , 2019, 8, 1081.	1.0	10
265	Differences in the regulation of inflammatory pathways in adolescent- and adult-onset first-episode psychosis. <i>European Child and Adolescent Psychiatry</i> , 2019, 28, 1395-1405.	2.8	10
266	Elevated Extracellular Free-Water in a Multicentric First-Episode Psychosis Sample, Decrease During the First 2 Years of Illness. <i>Schizophrenia Bulletin</i> , 2020, 46, 846-856.	2.3	10
267	A replication study of JTC bias, genetic liability for psychosis and delusional ideation. <i>Psychological Medicine</i> , 2022, 52, 1777-1783.	2.7	10
268	Cognitive remediation and brain connectivity: A resting-state fMRI study in patients with schizophrenia. <i>Psychiatry Research - Neuroimaging</i> , 2020, 303, 111140.	0.9	10
269	The Role of Premorbid IQ and Age of Onset as Useful Predictors of Clinical, Functional Outcomes, and Recovery of Individuals with a First Episode of Psychosis. <i>Journal of Clinical Medicine</i> , 2021, 10, 2474.	1.0	10
270	Synergistic effects of childhood adversity and polygenic risk in first-episode psychosis: the EU-GEI study. <i>Psychological Medicine</i> , 0, , 1-9.	2.7	10

#	ARTICLE	IF	CITATIONS
271	Cognitive clusters in first-episode psychosis. <i>Schizophrenia Research</i> , 2021, 237, 31-39.	1.1	10
272	Examining facial emotion recognition as an intermediate phenotype for psychosis: Findings from the EUGEI study. <i>Progress in Neuro-Psychopharmacology and Biological Psychiatry</i> , 2022, 113, 110440.	2.5	10
273	Mapping Retinal Abnormalities in Psychosis: Meta-analytical Evidence for Focal Peripapillary and Macular Reductions. <i>Schizophrenia Bulletin</i> , 2022, 48, 1194-1205.	2.3	10
274	Assessment of real-world daily-living skills in early-onset schizophrenia through the Life Skills Profile scale. <i>Schizophrenia Research</i> , 2013, 145, 95-100.	1.1	9
275	Thinking About Electroconvulsive Therapy: The Opinions of Parents of Adolescents with Schizophrenia Spectrum Disorders. <i>Journal of Child and Adolescent Psychopharmacology</i> , 2017, 27, 75-82.	0.7	9
276	Auditory hallucinations in first-episode psychosis: A voxel-based morphometry study. <i>Schizophrenia Research</i> , 2019, 209, 148-155.	1.1	9
277	Spatial Suppression and Sensitivity for Motion in Schizophrenia. <i>Schizophrenia Bulletin Open</i> , 2020, 1, .	0.9	9
278	Authors' reply to "on the existence of a linguistic distance in schizophrenia". <i>Psychological Medicine</i> , 2022, 52, 798-799.	2.7	9
279	Childhood Maltreatment, Educational Attainment, and IQ: Findings From a Multicentric Case-control Study of First-episode Psychosis (EU-GEI). <i>Schizophrenia Bulletin</i> , 2022, 48, 575-589.	2.3	9
280	Use of multiple polygenic risk scores for distinguishing schizophrenia-spectrum disorder and affective psychosis categories in a first-episode sample; the EU-GEI study. <i>Psychological Medicine</i> , 2023, 53, 3396-3405.	2.7	9
281	Facial Emotion Recognition in Psychosis and Associations With Polygenic Risk for Schizophrenia: Findings From the Multi-Center EU-GEI Case-Control Study. <i>Schizophrenia Bulletin</i> , 2022, 48, 1104-1114.	2.3	9
282	A functional variant provided further evidence for the association of <i>ARVCF</i> with schizophrenia. <i>American Journal of Medical Genetics Part B: Neuropsychiatric Genetics</i> , 2010, 153B, 1052-1059.	1.1	8
283	Therapeutic Approach to Delusional Disorder Based on Psychopathological Complexity. <i>Journal of Clinical Psychopharmacology</i> , 2015, 35, 201-202.	0.7	8
284	The oestrogen dysfunction hypothesis in schizophrenia: The need for an integrative approach to treat postmenopausal women. <i>Australian and New Zealand Journal of Psychiatry</i> , 2016, 50, 1207-1208.	1.3	8
285	Three-month paliperidone palmitate - a new treatment option for schizophrenia. <i>Expert Review of Clinical Pharmacology</i> , 2016, 9, 899-904.	1.3	8
286	Impact of <i>NTRK2</i> , <i>DRD2</i> and <i>ACE</i> polymorphisms on prolactin levels in antipsychotic-treated patients with first-episode psychosis. <i>Journal of Psychopharmacology</i> , 2018, 32, 702-710.	2.0	8
287	Influence of BDNF and MTHFR polymorphisms on hippocampal volume in first-episode psychosis. <i>Schizophrenia Research</i> , 2020, 223, 345-352.	1.1	8
288	The usefulness of Olanzapine plasma concentrations in monitoring treatment efficacy and metabolic disturbances in first-episode psychosis. <i>Psychopharmacology</i> , 2021, 238, 665-676.	1.5	8

#	ARTICLE	IF	CITATIONS
289	Interindividual variability of functional connectome in schizophrenia. <i>Schizophrenia Research</i> , 2021, 235, 65-73.	1.1	8
290	Metabolic polygenic risk scores effect on antipsychotic-induced metabolic dysregulation: A longitudinal study in a first episode psychosis cohort. <i>Schizophrenia Research</i> , 2022, 244, 101-110.	1.1	8
291	Baseline, visual deprivation and visual stimulation 99Tcm-HMPAO-related changes in visual cortex can be detected with a single-head SPET system. <i>Nuclear Medicine Communications</i> , 1996, 17, 480-484.	0.5	7
292	Recommendations for switching antipsychotics. A position statement of the Spanish Society of Psychiatry and the Spanish Society of Biological Psychiatry. <i>Revista De Psiquiatr�a Y Salud Mental (English Edition)</i> , 2011, 4, 150-168.	0.2	7
293	Electroconvulsive Therapy Practice in Catalonia. <i>Journal of ECT</i> , 2015, 31, 43-49.	0.3	7
294	Effectiveness, efficiency and efficacy in the multidimensional treatment of schizophrenia: Rethinking project. <i>Revista De Psiquiatr�a Y Salud Mental (English Edition)</i> , 2017, 10, 4-20.	0.2	7
295	A Case Study of Clozapine and Cognition. <i>Journal of Clinical Psychopharmacology</i> , 2018, 38, 152-153.	0.7	7
296	Detection of early psychotic symptoms: Validation of the Spanish version of the ‘‘Symptom Onset in Schizophrenia (SOS) inventory’’. <i>Psychiatry Research</i> , 2018, 261, 68-72.	1.7	7
297	Food craving and consumption evolution in patients starting treatment with clozapine. <i>Psychopharmacology</i> , 2019, 236, 3317-3327.	1.5	7
298	Association of extent of cannabis use and psychotic like intoxication experiences in a multi-national sample of first episode psychosis patients and controls. <i>Psychological Medicine</i> , 2021, 51, 2074-2082.	2.7	7
299	Variaci3n intraindividual en los niveles plasm3ticos de clozapina y norclozapina en la pr3ctica cl�nica. <i>Revista De Psiquiatr�a Y Salud Mental</i> , 2020, 13, 31-35.	1.0	7
300	Perceived major experiences of discrimination, ethnic group, and risk of psychosis in a six-country case-control study. <i>Psychological Medicine</i> , 2022, 52, 3668-3676.	2.7	7
301	Cognitive heterogeneity in the offspring of patients with schizophrenia or bipolar disorder: a cluster analysis across family risk. <i>Journal of Affective Disorders</i> , 2021, 282, 757-765.	2.0	7
302	Self-reported neurocognitive symptoms during COVID-19 lockdown and its associated factors in a sample of psychiatric patients. Results from the BRIS-MHC study. <i>European Neuropsychopharmacology</i> , 2021, 53, 7-18.	0.3	7
303	Risk factor assessment and counselling for 12 months reduces metabolic and cardiovascular risk in overweight or obese patients with schizophrenia spectrum disorders: The CRESSOB study. <i>Actas Espanolas De Psiquiatria</i> , 2016, 44, 20-9.	0.1	7
304	Cognitive Behavioral Therapy Program for Cannabis Use Cessation in First-Episode Psychosis Patients: A 1-Year Randomized Controlled Trial. <i>International Journal of Environmental Research and Public Health</i> , 2022, 19, 7325.	1.2	7
305	What have we learned from research into first-episode psychosis?. <i>Revista De Psiquiatr�a Y Salud Mental (English Edition)</i> , 2014, 7, 61-63.	0.2	6
306	Desarrollo profesional en investigaci3n traslacional en neurociencias y salud mental: educaci3n y formaci3n dentro del Centro de Investigaci3n Biom3dica en Red en Salud Mental. <i>Revista De Psiquiatr�a Y Salud Mental</i> , 2015, 8, 65-74.	1.0	6

#	ARTICLE	IF	CITATIONS
307	Adherence predicts symptomatic and psychosocial remission in schizophrenia: Naturalistic study of patient integration in the community. <i>Revista De Psiquiatr�a Y Salud Mental (English Edition)</i> , 2017, 10, 149-159.	0.2	6
308	Is cerebrovascular disease a silent condition in patients with chronic schizophrenia-related disorders?. <i>International Clinical Psychopharmacology</i> , 2017, 32, 80-86.	0.9	6
309	Personalized medicine begins with the phenotype: identifying antipsychotic response phenotypes in a first-episode psychosis cohort. <i>Acta Psychiatrica Scandinavica</i> , 2020, 141, 541-552.	2.2	6
310	Pre-training inter-rater reliability of clinical instruments in an international psychosis research project. <i>Schizophrenia Research</i> , 2020, 230, 104-107.	1.1	6
311	Birth weight and antipsychotic induced weight gain: A prenatal programming approach in the PEPs study. <i>Schizophrenia Research</i> , 2020, 218, 292-294.	1.1	6
312	Antipsychotic-Associated Weight Gain and Clinical Improvement Under Clozapine Treatment. <i>Journal of Clinical Psychopharmacology</i> , 2022, 42, 75-80.	0.7	6
313	Dried Blood Spot (DBS) as a useful tool to improve clozapine, aripiprazole and paliperidone treatment: From adherence to efficiency. <i>Revista De Psiquiatr�a Y Salud Mental</i> , 2022, 15, 230-237.	1.0	6
314	Coronary heart disease and psychological variables: is Type A enough to increase the risk?. <i>Personality and Individual Differences</i> , 1987, 8, 733-736.	1.6	5
315	Hypophyseal response to ECT: A higher and faster vasopressin peak. <i>Biological Psychiatry</i> , 1993, 33, 670-672.	0.7	5
316	The Relationship Between Plasma Haloperidol Concentrations and Clinical Results. <i>Archives of General Psychiatry</i> , 1996, 53, 1167.	13.8	5
317	�Deber�a considerarse la obesidad un factor limitante para el tratamiento con clozapina?. <i>Revista De Psiquiatr�a Y Salud Mental</i> , 2013, 6, 75-79.	1.0	5
318	One decade of the first episodes project (PEPs): Advancing towards a precision psychiatry. <i>Revista De Psiquiatr�a Y Salud Mental (English Edition)</i> , 2019, 12, 135-140.	0.2	5
319	White Noise Speech Illusions: A Trait-Dependent Risk Marker for Psychotic Disorder?. <i>Frontiers in Psychiatry</i> , 2019, 10, 676.	1.3	5
320	CIBERSAM: Ten years of collaborative translational research in mental disorders. <i>Revista De Psiquiatr�a Y Salud Mental (English Edition)</i> , 2019, 12, 1-8.	0.2	5
321	Influence of secondary sources in the Brief Negative Symptom Scale. <i>Schizophrenia Research</i> , 2019, 204, 452-454.	1.1	5
322	Dificultades en el parto y sintomatolog�a depresiva en la esquizofrenia. <i>Revista De Psiquiatr�a Y Salud Mental</i> , 2021, 14, 66-68.	1.0	5
323	Impact of previous tobacco use with or without cannabis on first psychotic experiences in patients with first-episode psychosis. <i>Schizophrenia Research</i> , 2021, 236, 19-28.	1.1	5
324	Clinical guideline for the treatment of dual pathology in the adult population. <i>Revista De Psicología De La Salud</i> , 2016, 28, 3.	0.2	5

#	ARTICLE	IF	CITATIONS
325	A longitudinal study of gene expression in first-episode schizophrenia; exploring relapse mechanisms by co-expression analysis in peripheral blood. <i>Translational Psychiatry</i> , 2021, 11, 539.	2.4	5
326	Negative schizophrenic symptoms as prefrontal cortex dysfunction: Examination using a task measuring goal neglect. <i>NeuroImage: Clinical</i> , 2022, 35, 103119.	1.4	5
327	ECT IN DISORGANIZED SCHIZOPHRENIA. <i>Journal of the American Academy of Child and Adolescent Psychiatry</i> , 2004, 43, 1191-1192.	0.3	4
328	Plasma homovanillic acid in adolescents with bulimia nervosa. <i>Psychiatry Research</i> , 2009, 170, 241-244.	1.7	4
329	Treatment patterns and health care resource utilization in a 1-year observational cohort study of outpatients with schizophrenia at risk of nonadherence treated with long-acting injectable antipsychotics. <i>Patient Preference and Adherence</i> , 2011, 5, 601.	0.8	4
330	Ziprasidone versus Olanzapine in the weight gain associated with the treatment of schizophrenia: A six-month double-blind randomized parallel group study. <i>European Journal of Psychiatry</i> , 2012, 26, 248-259.	0.7	4
331	Detection and management of agitation in psychiatry: A Delphi expert consensus study. <i>European Psychiatry</i> , 2016, 33, S170-S170.	0.1	4
332	The role of genetics in cognitive remediation in schizophrenia: A systematic review. <i>Schizophrenia Research: Cognition</i> , 2020, 19, 100146.	0.7	4
333	Intra-individual variation of clozapine and norclozapine plasma levels in clinical practice. <i>Revista De Psiquiatria Y Salud Mental (English Edition)</i> , 2020, 13, 31-35.	0.2	4
334	Identifying key transcription factors for pharmacogenetic studies of antipsychotics induced extrapyramidal symptoms. <i>Psychopharmacology</i> , 2020, 237, 2151-2159.	1.5	4
335	The longitudinal effect of antipsychotic burden on psychosocial functioning in first-episode psychosis patients: the role of verbal memory. <i>Psychological Medicine</i> , 2021, 51, 2044-2053.	2.7	4
336	Duration of Untreated Psychosis in First-Episode Psychosis is not Associated With Common Genetic Variants for Major Psychiatric Conditions: Results From the Multi-Center EU-GEI Study. <i>Schizophrenia Bulletin</i> , 2021, 47, 1653-1662.	2.3	4
337	The relationship of symptom dimensions with premorbid adjustment and cognitive characteristics at first episode psychosis: Findings from the EU-GEI study. <i>Schizophrenia Research</i> , 2021, 236, 69-79.	1.1	4
338	Relationship between cognition and age at onset of first-episode psychosis: comparative study between adolescents, young adults, and adults. <i>European Child and Adolescent Psychiatry</i> , 2021, , 1.	2.8	4
339	Is the effect of cognitive reserve in longitudinal outcomes in first-episode psychoses dependent on the use of cannabis?. <i>Journal of Affective Disorders</i> , 2022, 302, 83-93.	2.0	4
340	Prodromal phase: Differences in prodromal symptoms, risk factors and markers of vulnerability in first episode mania versus first episode psychosis with onset in late adolescence or adulthood. <i>Acta Psychiatrica Scandinavica</i> , 2022, 146, 36-50.	2.2	4
341	The role of BDNF and NGF plasma levels in first-episode schizophrenia: A longitudinal study. <i>European Neuropsychopharmacology</i> , 2022, 57, 105-117.	0.3	4
342	Shaped before birth: Obstetric complications identify a more severe clinical phenotype among patients presenting a first affective or non-affective episode of psychosis. <i>Journal of Psychiatric Research</i> , 2022, 151, 461-468.	1.5	4

#	ARTICLE	IF	CITATIONS
343	PLASMA LEVELS OF HALOPERIDOL AND CLINICAL RESPONSE IN SCHIZOPHRENIA. <i>Clinical Neuropharmacology</i> , 1992, 15, 354B.	0.2	3
344	Schizophrenia, Obsessive-Compulsive Disorder, and Tourette's Syndrome: A Case of Triple Comorbidity. <i>Journal of Neuropsychiatry and Clinical Neurosciences</i> , 1993, 5, 108-108.	0.9	3
345	Letter to the editor. <i>Acta Psychiatrica Scandinavica</i> , 2005, 112, 79-80.	2.2	3
346	Left amygdalar activation in deficit syndrome compared with non-deficit subjects with schizophrenia during the control task in a facial emotion recognition paradigm. <i>Psychiatry Research - Neuroimaging</i> , 2012, 203, 109-110.	0.9	3
347	Clozapine and agranulocytosis in Spain: Do we have a safer population? A 5-year haematologic follow-up. <i>Revista De Psiquiatr�a Y Salud Mental (English Edition)</i> , 2012, 5, 37-42.	0.2	3
348	Awareness of illness and suicidal behavior in delusional disorder patients. <i>Revista De Psiquiatria Clinica</i> , 2014, 41, 156-158.	0.6	3
349	Dignifying Electroconvulsive Therapy based on evidence. <i>Revista De Psiquiatr�a Y Salud Mental (English Edition)</i> , 2015, 8, 51-54.	0.2	3
350	When the healthcare does not follow the evidence: The case of the lack of early intervention programs for psychosis in Spain. <i>Revista De Psiquiatr�a Y Salud Mental (English Edition)</i> , 2017, 10, 78-86.	0.2	3
351	Long-acting injectable antipsychotics for the treatment of schizophrenia in Spain. <i>Revista De Psiquiatr�a Y Salud Mental (English Edition)</i> , 2019, 12, 92-105.	0.2	3
352	The prevention of relapses in first episodes of schizophrenia: The 2EPs Project, background, rationale and study design. <i>Revista De Psiquiatr�a Y Salud Mental (English Edition)</i> , 2021, 14, 164-176.	0.2	3
353	Identification of EP300 as a Key Gene Involved in Antipsychotic-Induced Metabolic Dysregulation Based on Integrative Bioinformatics Analysis of Multi-Tissue Gene Expression Data. <i>Frontiers in Pharmacology</i> , 2021, 12, 729474.	1.6	3
354	Prefrontal abnormalities, executive dysfunction and symptoms severity are modulated by COMT Val158Met polymorphism in first episode psychosis. <i>Revista De Psiquiatr�a Y Salud Mental</i> , 2021, , .	1.0	3
355	Schizophrenia and cerebrovascular disease. A description of a series and bibliographic reivew. <i>Actas Espanolas De Psiquiatria</i> , 2014, 42, 74-82.	0.1	3
356	Cortical thinning over two years after first-episode psychosis depends on age of onset. <i>NPJ Schizophrenia</i> , 2022, 8, 20.	2.0	3
357	Link between cognitive polygenic risk scores and clinical progression after a first-psychotic episode. <i>Psychological Medicine</i> , 2023, 53, 4634-4647.	2.7	3
358	La amplificaci�n somatosensorial en la esquizofrenia est� relacionada con la preservaci�n del rendimiento neuropsicol�gico. <i>Revista De Psiquiatr�a Y Salud Mental</i> , 2008, 1, 3-9.	1.0	2
359	Should obesity be a limiting factor for clozapine treatment?. <i>Revista De Psiquiatr�a Y Salud Mental (English Edition)</i> , 2013, 6, 75-79.	0.2	2
360	Documento de posicionamiento de consenso por el Colectivo de Psiquiatras por la Actualizaci�n de Clozapina. <i>Psiquiatria Biologica</i> , 2017, 24, 64-66.	0.0	2



#	ARTICLE	IF	CITATIONS
361	SiNoPsis: Single Nucleotide Polymorphisms selection and promoter profiling. <i>Bioinformatics</i> , 2018, 34, 303-305.	1.8	2
362	Difficulties in delivery and depressive symptomatology in schizophrenia. <i>Revista De Psiquiatr�a Y Salud Mental (English Edition)</i> , 2021, 14, 66-68.	0.2	2
363	Gene co-expression architecture in peripheral blood in a cohort of remitted first-episode schizophrenia patients. <i>NPJ Schizophrenia</i> , 2022, 8, .	2.0	2
364	The network structure of cognitive deficits in first episode psychosis patients. <i>Schizophrenia Research</i> , 2022, 244, 46-54.	1.1	2
365	Non-adherence to oral antipsychotics in schizophrenia: Relapse and therapeutic strategies in a 12-month observational study. <i>European Psychiatry</i> , 2011, 26, 1362-1362.	0.1	1
366	Systematic review of the Genomewide Association Studies (GWAS) in schizophrenia. <i>Revista De Psiquiatr�a Y Salud Mental (English Edition)</i> , 2011, 4, 218-227.	0.2	1
367	Building up careers in translational neuroscience and mental health research: Education and training in the Centre for Biomedical Research in Mental Health. <i>Revista De Psiquiatr�a Y Salud Mental (English)</i> Tj ETQq1 102784314rgBT /Ove		
368	B�squeda De Nuevos Biomarcadores De La Cognici�n En Esquizofrenia. <i>Schizophrenia Research: Cognition</i> , 2015, 2, 196-203.	0.7	1
369	Pattern of electroconvulsive therapy use in Spain: Proposals for an optimal practice and equitable access. <i>Revista De Psiquiatr�a Y Salud Mental (English Edition)</i> , 2017, 10, 87-95.	0.2	1
370	S69. A CASE STUDY OF CLOZAPINE AND COGNITION: FRIEND OR FOE?. <i>Schizophrenia Bulletin</i> , 2018, 44, S351-S351.	2.3	1
371	Relationship Between Antipsychotic Medications and Cerebrovascular Disease in Patients With Serious Mental Illness. <i>Journal of Psychiatric Practice</i> , 2018, 24, 72-78.	0.3	1
372	Epigenetic Studies in Psychotherapy: A Systematic Review. <i>Current Psychiatry Research and Reviews</i> , 2020, 16, 86-92.	0.1	1
373	Acute effects of a session of electroconvulsive therapy on brain-derived neurotrophic factor plasma levels. <i>Revista De Psiquiatr�a Y Salud Mental</i> , 2020, , .	1.0	1
374	Longitudinal Allometry of Sulcal Morphology in Health and Schizophrenia. <i>Journal of Neuroscience</i> , 2022, 42, 3704-3715.	1.7	1
375	Effectiveness of Cognitive Behavioural Therapy for Suicide in Schizophrenia: A Systematic Review. <i>Current Psychiatry Research and Reviews</i> , 2021, 18, .	0.1	1
376	Sex and substance use in first episode psychosis: Impact on clinical symptoms, psychosocial functioning and cognitive performance. <i>Revista De Psiquiatr�a Y Salud Mental</i> , 2022, , .	1.0	1
377	Letter to the editor. <i>Acta Psychiatrica Scandinavica</i> , 2005, 112, 78-78.	2.2	0
378	Spanish Adaptation and Validation of the Strauss-Carpenter Outcome Scale for Schizophrenia. <i>Revista De Psiquiatr�a Y Salud Mental (English Edition)</i> , 2009, 2, 150-159.	0.2	0



#	ARTICLE	IF	CITATIONS
379	Prevalence of Metabolic Syndrome in Spanish Patients with Schizophrenia and Overweight. <i>European Psychiatry</i> , 2009, 24, .	0.1	0
380	Forumclinic: An Interactive Program for Patients with Chronic Illnesses. , 2009, , .		0
381	El papel del placebo en ensayos clínicos en esquizofrenia. <i>Psiquiatría Biológica</i> , 2013, 20, 63-69.	0.0	0
382	Eficacia de los Ácidos grasos omega-3 como tratamiento suplementario en la esquizofrenia. <i>Psiquiatría Biológica</i> , 2013, 20, 8-13.	0.0	0
383	Algorithm-based protocol for the identification, management and treatment of psychiatric patients with acute psychomotor agitation. <i>European Psychiatry</i> , 2017, 41, S566-S566.	0.1	0
384	Quality indicators in the treatment of patients with depression, bipolar disorder or schizophrenia. Consensus study. <i>Revista De Psiquiatría Y Salud Mental (English Edition)</i> , 2018, 11, 66-75.	0.2	0
385	F245. COGNITIVE RESERVE DIFFERENCE IN AFFECTIVE AND NONAFFECTIVE PSYCHOSIS. <i>Schizophrenia Bulletin</i> , 2018, 44, S318-S318.	2.3	0
386	Are there differences in prodromal symptoms according to the age of onset of psychosis?. <i>European Neuropsychopharmacology</i> , 2019, 29, S553-S554.	0.3	0
387	Age at first episode modulates progressive cortical thinning in individuals with psychosis. <i>European Neuropsychopharmacology</i> , 2019, 29, S103-S104.	0.3	0
388	M60. EARLY VERSUS DELAYED PRESCRIPTION OF CLOZAPINE AND THE COGNITIVE PERFORMANCE ON SCHIZOPHRENIA. <i>Schizophrenia Bulletin</i> , 2020, 46, S157-S158.	2.3	0
389	S47. A MULTICENTER STUDY OF COGNITIVE RESERVE IN FIRST-EPISODE PSYCHOSIS. <i>Schizophrenia Bulletin</i> , 2020, 46, S50-S50.	2.3	0
390	P.530 Intestinal permeability and low-grade chronic inflammation in schizophrenia: do they influence cognition and cognitive reserve?. <i>European Neuropsychopharmacology</i> , 2020, 40, S297-S298.	0.3	0
391	P.537 Investigating the clinical features associated with specific family environment styles in first psychotic episodes. <i>European Neuropsychopharmacology</i> , 2020, 40, S302.	0.3	0
392	Clinical remission in a cohort of first-episode psychosis: Data from the PEPs study. <i>Psiquiatría Biológica</i> , 2021, 28, 1-8.	0.0	0
393	Role of Cingulate Gyrus during Wisconsin Card Sorting Test: A Single Photon Emission Computed Tomography (Spect) Study. <i>Key Topics in Brain Research</i> , 1997, , 119-123.	0.2	0
394	Conflicto de intereses en psiquiatría. <i>Revista De Psiquiatría Y Salud Mental</i> , 2019, 12, 201-206.	1.0	0
395	Impact of traumatic life events on clinical variables of individuals with first-episode psychosis and healthy controls. <i>International Journal of Social Psychiatry</i> , 2023, 69, 134-145.	1.6	0
396	Social cognition as a mediator between cognitive reserve and psychosocial functioning in patients with first episode psychosis. <i>European Psychiatry</i> , 2021, 64, S163-S163.	0.1	0

#	ARTICLE	IF	CITATIONS
397	P.0149 Cognitive reserve and cannabis use in first-episode psychoses. European Neuropsychopharmacology, 2021, 53, S107-S108.	0.3	0
398	Cultural adaptation to Spanish of the &#8220;Patient Satisfaction Survey&#8221; to assess satisfaction with electroconvulsive therapy (ECT).. Actas Espanolas De Psiquiatria, 2022, 50, 1-14.	0.1	0
399	Prefrontal abnormalities, executive dysfunction and symptoms severity are modulated by COMT Val158Met polymorphism in first episode psychosis. Revista De Psiquiatr�a Y Salud Mental (English) Tj ETQq1 1 0.784314 rgBT /Over	0.784314	0